Merck announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.
More Stories
‘Powell delivered the stock market to the Promised Land.’ Why the S&P 500 could soar past 6,000 by year-end.
Yardeni: Odds of a 1990s-like market boom have increased after Fed rate-cut.
Small-cap stocks post longest rally since 2021 after Fed rate cut. What’s next?
Small-cap stocks just saw their longest winning streak in three and a half years, after the Federal Reserve recalibrated its...
Traders face biggest index rebalancing in four years on Friday: Here’s what to watch for
Investors are facing the busiest quarterly rebalancing in about four years on Friday in a shakeup that could impact roughly...
Four things you need to know about Medicare drug costs and coverage in 2025
With Medicare prescription-drug benefits on the brink of a shake-up, enrollees who hope to minimize their costs at the pharmacy...
Trump Media & Technology Group’s stock hits low as insider stock-sale ban lifts
Trump Media & Technology Group Corp.’s stock dropped to its lowest level since it went public in March Friday, as...
The surprising math of immigration, Social Security and Medicare
Immigration will have an effect on your retirement — but it’s probably not what you think.